Combined with these studies, the therapeutic direction of IgAN and SLE can be offered with a method to target FcαRI or IgA, which can neutralize soluble FcαRI or unglycosylated IgA1 to interrupt the IgA–FcαRI interaction. This evidence concerns the gene CD79A and systemic lupus erythematosus.